Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress NPV of future cash flows…
Watch on earnings: Losmapimod quarterly prescription volume trends and year-over-year new patient starts in FSHD population, Cash and equivalents balance relative to quarterly operating cash burn rate (runway calculation), Clinical trial enrollment rates and data readout timelines for FTX-6058 sickle cell program.
One Sentence Summary:
Fulcrum Therapeutics: the story is balanced — losmapimod commercial uptake metrics: new patient starts, persistence rates, and quarterly prescription volume trends in fshd population.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
